Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of taselisib (GDC-0032) ± fulvestrant in advanced solid tumors and hormone receptor-positive breast cancer
jRCT2080222579Phase 1
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of taselisib / pictilisib in Non-hematologic malignancy and breast cancer (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd.
02
Drugs
taselisib / pictilisib
03
Conditions
Non-hematologic malignancybreast cancer
Beyond the preview
Go deeper on jRCT2080222579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222579.